Literature DB >> 11961142

Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition.

Lars H Jensen1, Axelle Renodon-Corniere, Irene Wessel, Seppo W Langer, Birgitte Søkilde, Elisabeth V Carstensen, Maxwell Sehested, Peter B Jensen.   

Abstract

Maleimide, N-ethyl-maleimide (NEM), and N-methyl-maleimide (NMM) were identified as potent catalytic inhibitors of purified human topoisomerase IIalpha, whereas the ring-saturated analog succinimide was completely inactive. Catalytic inhibition was not abrogated by topoisomerase II mutations that totally abolish the effect of bisdioxopiperazine compounds on catalytic inhibition, suggesting a different mode of action by these maleimides. Furthermore, in DNA cleavage assay maleimide and NEM could antagonize etoposide-induced DNA double-strand breaks. Consistently, maleimide could antagonize the effect of topoisomerase II poisons in three different in vivo assays: 1) In an alkaline elution assay maleimide protected against etoposide-induced DNA damage. 2) In a band depletion assay maleimide reduced etoposide-induced trapping of topoisomerase IIalpha and beta on DNA. 3) In a clonogenic assay maleimide antagonized the cytotoxicity of etoposide and daunorubicin on four different cell lines of human and murine origin. at-MDR cell lines with reduced nuclear topoisomerase IIalpha content are fully sensitive to maleimide, indicating that it is not a topoisomerase II poison in vivo. Our finding that topoisomerase II is sensitive to maleimide, NMM, and NEM but insensitive to succinimide demonstrates a strict requirement for the unsaturated ring bond for activity. We suggest that the observed antagonism in vitro and in vivo is caused by covalent modification of topoisomerase II cysteine residues reducing the amount of catalytically active enzyme sensitive to the action of topoisomerase II poisons.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961142     DOI: 10.1124/mol.61.5.1235

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  Cadmium is a catalytic inhibitor of DNA topoisomerase II.

Authors:  Xing Wu; Jack C Yalowich; Brian B Hasinoff
Journal:  J Inorg Biochem       Date:  2011-02-26       Impact factor: 4.155

2.  Photoclick Hydrogels Prepared from Functionalized Cyclodextrin and Poly(ethylene glycol) for Drug Delivery and in Situ Cell Encapsulation.

Authors:  Han Shih; Chien-Chi Lin
Journal:  Biomacromolecules       Date:  2015-06-03       Impact factor: 6.988

3.  GL3, a Novel 4β-Anilino-4'-O-Demethyl-4-Desoxypodophyllotoxin Analog, Traps Topoisomerase II Cleavage Complexes and Exerts Anticancer Activities.

Authors:  Xiao-Chun Yang; Shi-Jing Qian; Li Wang; Si-Da Liao; Ji Cao; Yong-Zhou Hu; Qiao-Jun He; Hong Zhu; Bo Yang
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

4.  Thiol-ene click hydrogels for therapeutic delivery.

Authors:  Prathamesh M Kharkar; Matthew S Rehmann; Kelsi M Skeens; Emanual Maverakis; April M Kloxin
Journal:  ACS Biomater Sci Eng       Date:  2016-01-11

5.  Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.

Authors:  Amitabh Jha; Chandrani Mukherjee; Ashok K Prasad; Virinder S Parmar; Manjula Vadaparti; Umashankar Das; Erik De Clercq; Jan Balzarini; James P Stables; Anuraag Shrivastav; Rajendra K Sharma; Jonathan R Dimmock
Journal:  Bioorg Med Chem Lett       Date:  2010-01-25       Impact factor: 2.823

6.  The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.

Authors:  Jack C Yalowich; Xing Wu; Rui Zhang; Ragu Kanagasabai; Marisa Hornbaker; Brian B Hasinoff
Journal:  Biochem Pharmacol       Date:  2012-04-04       Impact factor: 5.858

7.  Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

Authors:  Julie Scott; Robert T Dorr; Betty Samulitis; Terry H Landowski
Journal:  Cancer Chemother Pharmacol       Date:  2007-02-28       Impact factor: 3.333

8.  (-)-Xanthatin up-regulation of the GADD45γ tumor suppressor gene in MDA-MB-231 breast cancer cells: role of topoisomerase IIα inhibition and reactive oxygen species.

Authors:  Shuso Takeda; Momoko Noguchi; Kazumasa Matsuo; Yasuhiro Yamaguchi; Taichi Kudo; Hajime Nishimura; Yoshiko Okamoto; Toshiaki Amamoto; Mitsuru Shindo; Curtis J Omiecinski; Hironori Aramaki
Journal:  Toxicology       Date:  2013-01-08       Impact factor: 4.221

9.  (E)-4-aryl-4-oxo-2-butenoic acid amides, chalcone-aroylacrylic acid chimeras: design, antiproliferative activity and inhibition of tubulin polymerization.

Authors:  Maja D Vitorović-Todorović; Aleksandra Erić-Nikolić; Branka Kolundžija; Ernest Hamel; Slavica Ristić; Ivan O Juranić; Branko J Drakulić
Journal:  Eur J Med Chem       Date:  2013-01-11       Impact factor: 6.514

10.  Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions.

Authors:  Y Li; H Choi; Z Zhou; L Nolasco; H J Pownall; J Voorberg; J L Moake; J-F Dong
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.